Hypolipidemic effect of L-form S-methylmethionine sulfonium chloride in man.
The effect of L-form S-methylmethionine sulfonium chloride (L-MMSC) was studied in 26 patients with hypercholesterolemia during the oral administration period for 8 weeks (daily dose 1500 mg). The oral administration of L-MMSC resulted in the statistically significant decrease of serum total cholesterol (9.7%, P less than 0.001), but not of serum triglycerides. In addition, the statistically significant increases in serum high-density lipoprotein-cholesterol (HDL-cholesterol) and in the ratios of HDL-cholesterol/(total cholesterol) -- (HDL-cholesterol) and HDL-cholesterol/(total cholesterol) + (triglycerides) were observed by the administration of L-MMSC. The therapeutic effects in in-patients were more remarkable than those in outpatients.
D000328:Adult; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D014814:Vitamin U / Q000009:adverse effects / Q000494:pharmacology*; D014815:Vitamins / Q000494:pharmacology*
D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D014280:Triglycerides; D014815:Vitamins; D014814:Vitamin U; D002784:Cholesterol